NDAORALGRANULEPriority Review
Approved
Sep 2017
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
3/8 — Basic
Priority Review
Drug data last refreshed 4h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SOLOSEC (secnidazole) is an oral nitroimidazole antimicrobial approved in 2017 for the treatment of bacterial vaginosis in women. It is a single-dose granule formulation that works by disrupting bacterial DNA, offering a convenient one-time dosing regimen compared to multi-day antibiotic courses.
$0.07MPart D
Peak15.2 years to LOEProduct is at peak lifecycle stage with minimal Part D penetration (217 claims in 2023), indicating a niche market position with limited commercial scale and smaller branded team.
Mechanism of Action
Pharmacologic Class:
Nitroimidazole Antimicrobial
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on SOLOSEC positions you in a niche, stable therapeutic area with minimal competitive distractions but also limited growth trajectory. This role suits professionals seeking to build mastery in a focused women's health segment with a predictable, smaller-scale commercial operation.
Brand ManagerField Sales Representative
Worked on SOLOSEC at Evofem Biosciences? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.